Page last updated: 2024-08-21

indazoles and alectinib

indazoles has been researched along with alectinib in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Adachi, J; Araki, M; Friboulet, L; Fujita, N; Katayama, K; Katayama, R; Kukimoto-Niino, M; Kutkowska, J; Ma, B; Maruyama, K; Mizuta, H; Nishio, M; Oh-Hara, T; Okada, K; Okuno, Y; Sagae, Y; Sasakura, Y; Shirouzu, M; Simizu, S; Takagi, S; Takemoto, A; Tamai, K; Watanabe, K; Yanagitani, N	1

Other Studies

1 other study(ies) available for indazoles and alectinib

Article	Year
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer. Nature communications, 2021, 02-24, Volume: 12, Issue:1 Topics: Aminopyridines; Aniline Compounds; Animals; Apoptosis; Benzamides; Carbazoles; Cell Line; Cell Survival; Crizotinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Immunoblotting; Indazoles; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mice, Inbred BALB C; Molecular Dynamics Simulation; Neoplasm Recurrence, Local; Piperidines; Proto-Oncogene Proteins; Pyrazines; Pyrazoles; Receptor Protein-Tyrosine Kinases	2021

Article

Year

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.

Nature communications, 2021, 02-24, Volume: 12, Issue:1

Topics: Aminopyridines; Aniline Compounds; Animals; Apoptosis; Benzamides; Carbazoles; Cell Line; Cell Survival; Crizotinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Immunoblotting; Indazoles; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mice, Inbred BALB C; Molecular Dynamics Simulation; Neoplasm Recurrence, Local; Piperidines; Proto-Oncogene Proteins; Pyrazines; Pyrazoles; Receptor Protein-Tyrosine Kinases

2021